Dapsone
- Generic Name
- Dapsone
- Brand Names
- Aczone
- Drug Type
- Small Molecule
- Chemical Formula
- C12H12N2O2S
- CAS Number
- 80-08-0
- Unique Ingredient Identifier
- 8W5C518302
- Background
A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Phar...
- Indication
For the treatment and management of leprosy and dermatitis herpetiformis.
- Associated Conditions
- Acne Vulgaris, Bullous Systemic Lupus Erythematosus, Bullous dermatitis herpetiformis, Hansen's Disease, Pemphigus Vulgaris (PV), Relapsing Polychondritis, Mild Pneumocystis pneumonia, Mild Toxoplasma gondii encephalitis, Moderate Pneumocystis pneumonia, Moderate Toxoplasma gondii encephalitis, Refractory Idiopathic thrombocytopenic purpura
- Associated Therapies
- -
Metabolic Capacity of Israeli Populations
- Conditions
- Interventions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 1200
- Registration Number
- NCT00162383
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Jacobus Pharmaceutical
- Registration Number
- NCT00002043
- Locations
- 🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States
Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 96
- Registration Number
- NCT00000739
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇺🇸Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease, Chicago, Illinois, United States
🇺🇸Emory Univ. School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Atlanta, Georgia, United States
A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Jacobus Pharmaceutical
- Registration Number
- NCT00002283
- Locations
- 🇺🇸
Jacobus Pharmaceutical Co, Princeton, New Jersey, United States
A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 600
- Registration Number
- NCT00000991
- Locations
- 🇺🇸
Chicago Children's CRS, Chicago, Illinois, United States
🇺🇸Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
🇺🇸Case CRS, Cleveland, Ohio, United States
Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole-Trimethoprim and Dapsone and Their Hydroxylamine Metabolites
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 48
- Registration Number
- NCT00000826
- Locations
- 🇺🇸
University of Washington AIDS CRS, Seattle, Washington, United States
🇺🇸Ucsf Aids Crs, San Francisco, California, United States
Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- U.S. Bioscience
- Target Recruit Count
- 20
- Registration Number
- NCT00002120
- Locations
- 🇺🇸
Los Angeles County / Health Research Assoc / Drew Med Ctr, Los Angeles, California, United States
A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 700
- Registration Number
- NCT00000802
- Locations
- 🇺🇸
Case CRS, Cleveland, Ohio, United States
🇺🇸Ucsd, Avrc Crs, San Diego, California, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
A Study of Pentamidine Plus Dapsone in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients Who Cannot Take Trimethoprim or Sulfonamides
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 400
- Registration Number
- NCT00001028
- Locations
- 🇺🇸
Community Consortium of San Francisco, San Francisco, California, United States
🇺🇸Denver CPCRA / Denver Public Hlth, Denver, Colorado, United States
🇺🇸Wilmington Hosp / Med Ctr of Delaware, Wilmington, Delaware, United States
A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim in the Treatment of Mild-to-Moderate PCP in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 290
- Registration Number
- NCT00000640
- Locations
- 🇺🇸
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
🇺🇸Methodist Hosp. of Indiana, Indianapolis, Indiana, United States
🇺🇸Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.